Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Collier

Showing results (381-390 of 508) with videos related to

Pageof 51
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2017
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysisAlexander J Stockdale, Matthew J Saunders, Mark A Boyd, et al.
Bioresearch Open Access|February 11, 2016
A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons LearnedAnn C Collier, Tae-Wook Chun, Janine Maenza, et al.
AIDS (London, England)|August 16, 2001
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppressionD V Havlir, P B Gilbert, K Bennett, et al.
AIDS (London, England)|September 24, 2016
Long-term body composition changes in antiretroviral-treated HIV-infected individualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
Archives of Neurology|January 16, 2008
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemScott Letendre, Jennifer Marquie-Beck, Edmund Capparelli, et al.
International Journal of STD & AIDS|August 24, 2013
Neurocognitive impairment in HIV-infected individuals with previous syphilisC M Marra, R Deutsch, A C Collier, et al.
Plos One|June 7, 2013
Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine designPratima Kunwar, Natalie Hawkins, Warren L Dinges, et al.
The Journal of Infectious Diseases|February 22, 2001
Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapyA Seth, J Markee, A Hoering, et al.
AIDS (London, England)|February 9, 2012
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentrationDavid Croteau, Brookie M Best, Scott Letendre, et al.
Pageof 51

Showing results (381-390 of 508) with videos related to

Sort By:
Pageof 51
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2017
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysisAlexander J Stockdale, Matthew J Saunders, Mark A Boyd, et al.
Bioresearch Open Access|February 11, 2016
A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons LearnedAnn C Collier, Tae-Wook Chun, Janine Maenza, et al.
AIDS (London, England)|August 16, 2001
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppressionD V Havlir, P B Gilbert, K Bennett, et al.
AIDS (London, England)|September 24, 2016
Long-term body composition changes in antiretroviral-treated HIV-infected individualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
Archives of Neurology|January 16, 2008
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemScott Letendre, Jennifer Marquie-Beck, Edmund Capparelli, et al.
International Journal of STD & AIDS|August 24, 2013
Neurocognitive impairment in HIV-infected individuals with previous syphilisC M Marra, R Deutsch, A C Collier, et al.
Plos One|June 7, 2013
Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine designPratima Kunwar, Natalie Hawkins, Warren L Dinges, et al.
The Journal of Infectious Diseases|February 22, 2001
Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapyA Seth, J Markee, A Hoering, et al.
AIDS (London, England)|February 9, 2012
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentrationDavid Croteau, Brookie M Best, Scott Letendre, et al.
Pageof 51